News

A global clinical trial testing SKY-0515, Skyhawk Therapeutics’ daily oral therapy for Huntington’s disease, will soon start recruiting adults with the genetic condition in the U.S., Canada, and the U.K. Regulatory authorities in all three countries have granted permission to open sites for the worldwide portion (004-WW,…

An early-stage clinical trial designed to test a novel stem cell therapy — one designed to replace lost or damaged nerve cells in the brain — in people with Huntington’s disease is now recruiting adults with the genetic condition at its single site in California. The Phase 1/2 trial, dubbed…

An oral compound now being tested as a potential treatment for several neurodegenerative conditions was shown, in multiple laboratory models, to reduce the toxic protein clumps in nerve cells that drive Huntington’s disease. These findings suggest that the compound, called Anle138b, may also be a possible therapeutic…

Latus Bio plans to submit an application with the U.S. Food and Drug Administration (FDA) to move LTS-201, a one-time gene therapy for Huntington’s disease, into clinical trials. The application, which the company expects to file in the current quarter, leverages promising results in Huntington’s animal models showing…

Understanding underlying disease processes, reframing challenges, and using self-care techniques can help a person caring for someone who has Huntington’s disease build a sustainable caregiving practice, according to social worker Amy Lemke, PhD. Caring for a Huntington’s patient is like captaining a boat through a storm, Lemke, clinic coordinator…

Several late-stage clinical trials are now recruiting participants to test whether three experimental oral therapies can slow the progression of Huntington’s disease, with active or planned sites in the U.S. Representatives from three pharmaceutical companies described the development status of those therapies in a clinical trial showcase at the…

SOM Biotech is preparing to launch a global late-stage clinical trial to evaluate whether SOM3355, its experimental oral therapy, can safely and effectively ease movement problems and other symptoms in people with Huntington’s disease. If positive, data from the upcoming Phase 3 trial, which is expected to start…

A social worker and Huntington’s disease advocate says planning ahead for emergencies — and paying attention to early signs of changing symptoms and needs — can help support better care during a crisis for people with the genetic condition. The key, according to Carlette McDaniels, a therapist and clinical social worker…

Every member of the Huntington’s disease community — patients, their family members, friends, and supporters — plays a crucial role in advocating for legislative and policy changes that will make a better future for people with the genetic disorder. That’s the message from Phyllis Foxworth, senior manager of advocacy…

Huntington’s Disease Society of America (HDSA) leaders at the group’s 41st annual convention unveiled a new strategic plan and mission statement to meet the needs of Huntington’s disease patients, including plans to expand research programs and Centers of Excellence and build a strong network to fight the disease.